KRAS and pancreatic neoplasm: First, we compared fluid-phase uptake in KrasG12D MEFs and KRAS-mutant human pancreatic (MIA PaCa-2) and lung (A549) cancer cells with the corresponding KRAS wild-type cells (MEFs, BXPC-3 human pancreatic cancer cells, and H522 human lung cancer cells).